Sign in to view content

Therapeutic Horizons for Dry AMD

Robert L. Avery, MD

Video
Published 2019

Related

Prophylaxis Intravitreal Aflibercept Against Conversion to Neovascular AMD in High-Risk Eyes (PRO-CON): 24-Month Results
Jeffrey S. Heier, MD
Annual Meeting Talks
2019
Baseline Characteristics in the Phase 2 GOLDEN Study of IONIS-FB-LRx, an Investigational Antisense Oligonucleotide Designed to Treat AMD-Associated Geographic Atrophy
Glenn J. Jaffe, MD
Annual Meeting Talks
2022
Dry AMD Symposium 2
Annual Meeting Talks
2020

Category: AMD-Non-Neovascular

See more